Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy by unknown
RESEARCH ARTICLE Open Access
Comparative evaluation of patients’ and
physicians’ satisfaction with interferon
beta-1b therapy
Uwe Klaus Zettl1, Ulrike Bauer-Steinhusen2, Thomas Glaser2, Klaus Hechenbichler3, Michael Hecker1*, for the Study
Group
Abstract
Background: Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success
particularly depends on adherence to therapeutic regimens and patients’ perception of treatment efficacy. The latter is
strongly influenced by the confidence in the involved health care professionals and the relationship to the treating
physician.
Methods: In this report, we considered physicians’ and patients’ evaluation of satisfaction with interferon beta-1b
treatment efficacy for assessing the congruence in ratings. Data were queried in a study conducted between
2009 and 2013.
Results: After 6 months of therapy, > 80 % of the patients and physicians (N = 445) showed high degrees of
satisfaction regarding interferon beta-1b treatment, with only few physicians and patients (≤2.0 %) rating “not
satisfied”. The proportion of patients rating with the same category as their physicians was similar after 6 months
(47 % congruence) and at the 24 months/study end visit (49 %). Discrepancies between ratings were observed
with respect to study end: for patients with premature study end, more patients and physicians rated being not
satisfied with the therapy, accompanied by a considerably lower congruence of 33 % compared to 54 % for
patients receiving the therapy for at least 2 years and completing the study regularly.
Conclusions: Regular communication between physicians and patients about their perception of therapy might
improve alignment of treatment evaluation and could result in increased therapy persistence. In addition, patients’
willingness to perform a long-term therapy − even in the absence of disease symptoms −might be promoted by
repeated exchange between health care providers and patients with regard to realistic treatment expectations.
Trial registration: ClinicalTrials.gov NCT00902135 (registered May 13, 2009).
Keywords: Multiple Sclerosis, Interferon beta-1b, Treatment Satisfaction, Patient-Physician Relationship, Therapy
Adherence
Background
Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system and affects more than
2.5 million individuals worldwide [1]. Due to the chronic
nature of the disease and the preventive character of ap-
proved disease-modifying drugs (DMD), long-term treat-
ment of patients is indispensable. Various therapeutic
agents with diverse routes of administration and consid-
erable differences in the safety profiles are available.
Treatment with first-line DMD such as interferon beta-
1b is well-established and well-tolerated [2, 3]. However,
adherence to treatment regimens and persistence to
therapy play central roles for therapeutic success. In par-
ticular, adverse events and (perceived) lack of efficacy
often interfere with treatment initiation and long-term
treatment continuation [4, 5]. Management of common
adverse events − in part through specific nursing support
programs and/or by dose titration at therapy onset − as
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well as education of patients with respect to reasonable
expectations and knowledge of associated risks and be-
nefits can prevent therapy discontinuation and increase
satisfaction of patients [2, 4, 6].
Patients‘ and physicians‘ opinions on therapy might
differ remarkably, as known from a survey among dia-
betic patients who were recommended to start long-term
insulin therapy [7]. Therefore, recognizing and under-
standing patients‘ concerns regarding therapeutic options
can be critical for therapy initiation and subsequent com-
pliance [8]. In addition, accommodating patients‘ prefe-
rences regarding the physician’s role (e.g., the desire to be
or not to be involved in the decision making, and the
mode of communication) might have an impact on patient
adherence to an agreed treatment as well as on health
benefits resulting from sense of autonomy and satisfaction
with the decision [9].
Here, we report our results from a prospective national
cohort study with comparison of patients’ and physicians’
satisfaction with interferon beta-1b therapy.
Methods
The data are based on a prospective, non-interventional,
open-label, national cohort study, BETAPATH, which was
designed to assess the utility of an electronic patient diary
in MS patients treated with interferon beta-1b (Betaferon®).
The study was conducted in Germany between 04/2009
and 12/2013 [10]. Prerequisites for enrollment were con-
firmed clinically isolated syndrome (CIS) or relapsing-
remitting MS (RRMS) and appropriate age (≥18 years). In
addition, patients were included in this study only after ini-
tiation of treatment with interferon beta-1b and completion
of the initial dose escalation. Patients were followed for a
period of 24 months after the baseline visit and had to give
written informed consent. The study was conducted in
accordance with the Declaration of Helsinki, approved by
the Ethics Committee of the Ärztekammer Nordrhein (03/
2009), and registered at ClinicalTrials.gov (NCT00902135).
Standardized case report forms (CRF) were used at the
initial visit, all follow-up visits, and the final visit. The
final visit (study end) was after 24 months for study
completers, whereas for patients who discontinued the
study prematurely, it was the documented end of obser-
vation at any previous time point. In the CRF, the treat-
ing physicians recorded the date, disease course and
progression, cognitive state, and changes in therapy [10].
At follow-up visits, the physicians also evaluated their
satisfaction concerning the efficacy of interferon beta-1b
therapy with regard to the individual case. In addition, at
6, 12, and 24 months/study end, patients were queried
on separate questionnaires addressing health-related
issues such as quality of life, fatigue, depression, and
satisfaction with therapy. Satisfaction ratings were per-
formed by use of 4 categories (very satisfied, satisfied,
neutral, or not satisfied). For the analysis of congruence in
these ratings, cases with missing data were omitted, physi-
cians’ ratings were taken as a basis, and the proportion of
patients rating with the same category was calculated.
Adherence to the treatment regimen as well as side ef-
fects were investigated within the BETAPATH study as
well. To assess the regularity of treatment for the individ-
ual patients, the number of injections as recorded in the
electronic diary was analyzed. Non-adherence was defined
as >5 missed injections per 6-month interval as previously
described [11]. Drug-related adverse events (AE), which
occurred during or after injection of interferon beta-1b
and not later than 28 days after the end of observation,
were recorded using the MedDRA coding system. Baseline
characteristics and data on adherence and persistence to
treatment have been published elsewhere [10, 11].
Results
Satisfaction with interferon beta-1b therapy
A total of 669 patients participated in the BETAPATH
study [11]. For the present study, a subset of this cohort
was considered, because the question on satisfaction
with interferon beta-1b therapy was not in all cases
answered simultaneously by both the patient and the
physician. Satisfaction with the therapy was evaluated
after 6 months by N = 445 patients (125 men and 320
women) and their physicians. At study end, satisfaction
was evaluated by N = 353 physicians/patients (98 men
and 255 women) (Table 1). The regular study end after
24 months was achieved by N = 266 of these 353 cases,
whereas N = 87 patients terminated the study prema-
turely (Table 2, Additional file 1). Reasons for premature
study end were diverse: N = 70 patients quit the treat-
ment, N = 7 patients were tired of questionnaires, N = 3
patients moved to another place, and N = 7 indicated
other reasons.
M satisfied or very satisfied with treatment efficacy
throughout the study. At study end, 79.0 % of the physi-
cians chose the ratings “very satisfied” or “satisfied”,
compared to 86.7 % at the 6 months visit. Satisfaction
was lower in patients’ opinion: 74.8 % of the patients rated
“very satisfied” or “satisfied” according to the questionnaire
at the final visit (83.1 % at the 6 months visit) (Fig. 1). Only
a minority of physicians was not satisfied with the treat-
ment (6.8 % at final visit and 2.0 % at month 6). This was
similar to the patients’ point of view: 7.6 % of the patients
were not satisfied at study end as documented in the ques-
tionnaires (1.8 % at the 6 months visit) (Fig. 1).
Differences in therapy evaluation were observed at the
study end visit with respect to study termination: only
40.2 % of the patients who prematurely terminated the
study chose the ratings “very satisfied” or “satisfied”,
compared to 86.1 % of the patients receiving interferon
beta-1b for at least 2 years and completing the study
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regularly. Differences became also obvious at study
end within the category “not satisfied” (1.9 % of the pa-
tients with regular termination [N = 5] vs. 25.3 % of the
patients with premature termination [N = 22]). How-
ever, absolute numbers of not satisfied patients were
small. Evaluations of the physicians were similar to pa-
tients’ opinion although a higher proportion of physi-
cians was “very satisfied/satisfied” (49.4 %) and a lower
proportion rated with “not satisfied” (21.8 %) in the
case that the patients terminated the study prema-
turely (Fig. 1b).
Congruence of ratings
Total congruence rates (that is, the degree of agreement
between patients and physicians) were 47 % after 6 months
and 49 % at the 24 months/study end visit (Table 2). On
closer consideration of the category “very satisfied”, the
congruence between physicians’ ratings of the therapy in
the CRF compared to self-documentation of the patients
in the questionnaire was even higher with 62.9 % at month
6 and 63.2 % at the 24 months/study end visit. With de-
creasing satisfaction rating, divergences became more pro-
nounced in the categories “neutral” and “not satisfied”
(congruence rates < 35 %) (Fig. 2a, b, Table 2).
Data review with respect to study termination revealed
relevant differences in congruence of therapy ratings: total
congruence at study end varied from 54 % for patients
with regular study end to 33 % for patients with premature
study end. Patients with regular study end and their physi-
cians concordantly chose the rating “very satisfied” in
64.3 % of cases compared to 53.8 % when considering pa-
tients with premature study end. The divergence was even
greater in the categories “satisfied” (52.4 % upon regular
end vs. 26.7 % upon premature end) and “not satisfied”
(0 % vs. 42.1 %). In the latter case, however, the total num-
ber of patients/physicians was low (Fig. 2c, d, Table 2).
Adherence and side effects
For the subgroup of patients who received an electronic
patient diary (instead of a conventional paper diary) in
the BETAPATH study, adherence to interferon beta-1b
injection therapy could be evaluated. The electronic
diary was used by 234 and 138 patients out of the 445
and 353 patients who rated their satisfaction with ther-
apy (together with their physicians) after 6 months and
at the final study visit, respectively (Additional file 1).
Within the first 6 months, 158 patients (67.5 %) docu-
mented less than 6 missed injections, and within the last
12 months of the study, 64 patients (46.4 %) were con-
sidered adherent to the injection schedule. However,
Table 2 Congruence of ratings of patients (questionnaire) and their physicians (CRF)
6 Months 24 Months/study end Regular study end Premature study end
Congruence Congruence Congruence Congruence
Total N N % Total N N % Total N N % Total N N %
Total 445 353 266 87
Very satisfied 140 88 62.9 125 79 63.2 112 72 64.3 13 7 53.8
Satisfied 246 107 43.5 154 73 47.4 124 65 52.4 30 8 26.7
Neutral 40 9 22.5 37 11 29.7 18 5 27.8 19 6 31.6
Not satisfied 9 3 33.3 24 8 33.3 5 0 0.0 19 8 42.1
Not specified 10 2 20.0 13 1 7.7 7 1 14.3 6 0 0.0
Total congruence rate 209 47 % 172 49 % 143 54 % 29 33 %
CRF case report forms, total N total number of patients‘ and physicians‘ assessments available for congruence analysis, N number of patients with ratings
congruent to physicians‘ evaluation
Table 1 Clinical and demographic characteristics of the patients
at study onset
Evaluation of satisfaction
after 6 months (N = 445)
Evaluation of satisfaction
at study end (N = 353)
Sex, N (%)
Male 125 (28.1) 98 (27.8)
Female 320 (71.9) 255 (72.2)
Age (years),
mean (SD)




3.3 (5.8) 3.6 (6.1)
Number of relapses
(last 2 years), mean
(SD)
1.6 (1.2) 1.6 (1.4)
CIS, N (%) 22 (4.9) 16 (4.5)
RRMS, N (%) 423 (95.1) 337 (95.5)
EDSS, mean (SD) 2.0 (1.4) 2.0 (1.4)
Previous treatment,
N (%)
No 334 (75.1) 258 (73.1)
Yes 110 (24.7) 94 (26.6)
Missing 1 (0.2) 1 (0.3)
CIS clinically isolated syndrome, EDSS expanded disability status scale, RRMS
relapsing-remitting multiple sclerosis, SD standard deviation
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(non-)adherence was not associated with satisfaction with
therapy. The percentage of patients rating “very satisfied”
was > 43 % in the group of adherent patients and in the
group of non-adherent patients after 6 months and after
24 months/at study end. Conversely, only < 7 % rated “not
satisfied” in both patient groups and at both time points.
Drug-related AE were reported by the physicians during
the observational period for 65 (18.4 %) out of the 353 pa-
tients (Additional file 1). The most common AE were in-
jection site reactions (N = 24), influenza-like symptoms
(N = 16), and headache (N = 6). Of the patients with AE,
16.9 % rated “very satisfied” and 15.4 % rated “not satis-
fied” with the therapy after 24 months/at study end. For
comparison, 43.1 % and 5.9 % of the patients without AE
were “very satisfied” and “not satisfied”, respectively.
Discussion
Patients often complain about a lack of information and
difficulties in making a qualified therapeutic choice. Al-
though the treating neurologist is crucially responsible for
starting or changing a DMD treatment in MS, stopping a
treatment is mainly based on patients‘ decision [5]. There-
fore, communication between patient and physician and
close cooperation are important for a consensual opinion
on a given therapy, as this has an impact on adherence and
persistence to therapeutic regimens [12–14]. We investi-
gated the patient-physician relationship by evaluating physi-
cians’ and patients’ individual ratings of the Betaferon®
therapy as well as their congruence.
The degrees of satisfaction were high: most physicians
and patients (around 80 %) chose the categories “very
satisfied“ or “satisfied“. More patients chose the rating
“very satisfied” than physicians after 6 months. We can
only speculate if this difference is due to a poor relation-
ship between some physicians and patients or if patients
feel committed to more positive opinions regarding ther-
apy in the setting of a study. Therapy ratings of physi-
cians and MS patients have not been addressed in
parallel previously in the literature. However, in two
cross-sectional surveys with respect to satisfaction with
botulinum toxin for treating post-stroke spasticity, simi-
larly high satisfaction rates were observed (88.6 % of pa-
tients and 94.2 % of physicians were satisfied with the
treatment) [15].
In this study, discrepancies in patient ratings were ob-
served after substratification for study termination. For
Fig. 1 Satisfaction with interferon beta-1b therapy. a Physicians' and patients’ ratings of the therapy 6 months after the start of treatment as
documented by the physicians in case report forms (CRF) and by the patients in a separate questionnaire. b Physicians' and patients’ ratings of
the therapy at the final visit (24 months/study end), with substratification for patients with regular or premature study termination. pat. = patients;
phys. = physicians; quest. = questionnaire
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instance, 1.9 % of the patients with regular study end
were not satisfied with the therapy after 24 months,
whereas, as expected, this proportion was remarkably
higher among patients who discontinued the study pre-
maturely (25.3 %). This trend was also observed in the
physicians’ ratings: for patients with premature study
end, 21.8 % of the respective physicians were “not satis-
fied”. However, after 6 months, only few patients and
physicians chose this category, and no predictions with
regard to treatment discontinuation of unsatisfied pa-
tients in the long-term course of the study could be
made. Data from an observational study with RRMS
Fig. 2 Congruence of physicians’ and patients’ evaluation of the therapy. Comparison of physicians’ and patients’ ratings of the interferon beta-1b
therapy for multiple sclerosis (a) at the 6 months visit and (b) at the 24 months visit/study end, substratified for (c) regular and (d) premature study
termination. CRF = case report forms; shaded areas = proportion of congruent ratings of patients and physicians
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patients indicated a significant association of adherence
and overall patient satisfaction with therapy [16]. Thus,
poor satisfaction with treatment might be a predictor of
therapy adherence and continuation. In our data, adher-
ence to therapy as recorded in the electronic patient
diary was not related to better satisfaction ratings. This
suggests that patients are not necessarily not satisfied
with the treatment if they simply forget injections or if
they are tired of documentation.
Patients’ and physicians’ consensus in the ratings of ther-
apy was 47 % after 6 months and 49 % at the 24 months/
study end visit. However, the total congruence rate was
only 33 % with respect to patients who discontinued the
study, while it was 54 % for patients completing the study
and continuing the treatment with interferon beta-1b to
the 24 months visit. Deficiencies in documentation (e.g.,
CRF documentation with temporal distance to the pa-
tient’s visit) might have influenced this outcome. Mohr
and coworkers found that overoptimistic attitudes towards
therapy before treatment initiation are conversely associ-
ated with therapy continuation [17]. Empathic relations
between physicians and patients might reveal unrealistic
opinions and help counteracting therapy discontinuation
by proper education of patients. An improved adherence
was observed if the treating neurologists involved the
patients in the treatment plans at the onset of therapy
[16] − pointing to the importance of the patient-physician
relationship and shared decision making. Due to the asso-
ciation between patients’ perception of their relationship
with physicians and patients’ satisfaction with the treat-
ment, the involvement of MS patients is crucial for the
best long-term treatment outcomes [18].
We observed that patients who were not satisfied
oftentimes showed therapeutic side effects, as reflected
by the higher rate of AE in this group. It is thus import-
ant to continuously educate the patients in how to pre-
vent and manage drug-related AE [19], e.g., by rotating
injection sites. In addition, other factors deteriorating
patient satisfaction and treatment adherence might arise
in the course of therapy, e.g., depression or changes in
the personal situation [12, 13], and their impact seems
to be influenced by the offered support of health care
professionals [20].
The clinical practice environment is evolving, altering
the daily tasks performed by physicians and other health
care workers [21]. Primary care physicians spend more
time supervising assistants and less time listening to pa-
tient concerns. On the contrary, the roles of nurses and
medical assistants are increasingly important [22]. As
physicians often cannot invest the required amount of
time in the practice setting [14], MS nurses can provide
personal services, and they are the preferred health care
workers for a majority of patients to discuss their prob-
lems [4, 12, 23]. Besides provision of information and
reinforcement of motivation to continue DMD therapy,
they can also support patients in the use of autoinjectors
in order to minimize anxiety associated with self-
administered injections, which might be a barrier to
maintenance of treatment [12]. More regular contact by
telephone from health care providers may also help to
confirm adequate compliance. In addition, the involvement
of family members into treatment plans can improve ad-
herence to therapy [16]. Multidisciplinary approaches in
therapy and psychological support are important factors in
patients’ opinion [24]. In consequence, the interpersonal
relationship between the patient and the physician is one
determinant of patient satisfaction among others [25, 26].
Conclusions
In summary, overall physicians’ and patients’ satisfaction
with efficacy of interferon beta-1b treatment was high.
Performing a congruence analysis revealed discrepancies,
especially in case of patients who later discontinued the
therapy. It seems advisable to regularly assess and align
patients’ and physicians’ evaluation of treatment satisfac-
tion during scheduled appointments, with the aim of iden-
tifying reasons for dissatisfaction. Therapeutic side effects
and emerging psychological symptoms (e.g., depression)
might explain deviations from the physician’s opinion and
provoke non-adherence to therapy [12, 19, 27]. Other
health care professionals also have an impact on patients’
satisfaction with treatment. Consequently, optimized com-
munication across multiple disciplines and coordination
of continuity in medical care are needed to maintain effi-
cacy of long-term DMD treatment in MS.
Additional file
Additional file 1: Full data set used for congruence analysis. Satisfaction
with interferon beta-1b therapy as evaluated by patients and their physicians
after 6 months of treatment and at the 24 months/study end visit. For a
subgroup of patients, records of an electronic patient diary allowed to assess
adherence to the injection schedule in the first 6 months and in the last
12 months of the study. Moreover, the table provides the information, for
which patients drug-related adverse events were reported. (XLSX 30 kb)
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